<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2023.1064760</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>First report on severe septic shock associated with human Parvovirus B19 infection after cardiac surgery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Xiang</surname>
<given-names>Chunlin</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2041062"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Xiaoxiao</given-names>
</name>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2245926"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Youkang</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Tianlong</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1978167"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Xuemei</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiaoqin</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1950823"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Xiaobo</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Yiping</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Department of Intensive Care Unit, Sichuan Academy of Medical Sciences and Sichuan Provincial People&#x2019;s Hospital</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Li Ang, First Affiliated Hospital of Zhengzhou University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Kwame Kumi Asare, University of Cape Coast, Ghana; Yu&#x2019;e Liu, Tongji University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Yiping Wang, <email xlink:href="mailto:297285600@qq.com">297285600@qq.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1064760</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>10</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>03</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Xiang, Wu, Wei, Li, Tang, Wang, Zhang, Huang and Wang</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Xiang, Wu, Wei, Li, Tang, Wang, Zhang, Huang and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Human Parvovirus B19 (PB19) is a single-stranded DNA virus. Septic shock from viremia is rare with PB19; however, this infection can progress to life-threatening conditions. We report the first case of severe septic shock associated with a PB19 infection after cardiac surgery.</p>
</sec>
<sec>
<title>Case Presentation</title>
<p>A 50-year-old Chinese woman received elective double metal valve replacement, including the aortic valve and the mitral valve, under cardiopulmonary bypass (CPB) and suffered severe septic shock on postoperative day (PD) 30. Through the detection of PB19-specific nucleic acids in blister fluid and serum samples <italic>via</italic> metagenomic next-generation sequencing (mNGS), positive serum PB19 IgM and no other proven infection, acute PB19 infection was confirmed. After five days of combined treatment, no further fever or abdominal discomfort was noted, and the patient&#x2019;s circulation gradually became stable without vasoactive medications.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>PB19 may be an unrecognized cause of septic shock, rash, fever of unknown origin or multiple systemic signs and symptoms, especially in immunosuppressed and immunocompetent critically ill patients. Investigations for viral aetiology are needed.</p>
</sec>
</abstract>
<kwd-group>
<kwd>human Parvovirus B19</kwd>
<kwd>infection</kwd>
<kwd>septic shock</kwd>
<kwd>cardiac surgery</kwd>
<kwd>metagenomic next generation sequencing</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="42"/>
<page-count count="7"/>
<word-count count="3221"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>PB19 is a single-stranded DNA virus that causes many clinical disorders, of which the most common are erythema infectiosum (EI), aplastic crisis complicating chronic haemolytic anaemia, self-limiting arthritis, and hydrops foetalis, which lack specificity (<xref ref-type="bibr" rid="B26">Meyer, 2003</xref>; <xref ref-type="bibr" rid="B22">Landry, 2016</xref>). Septic shock from viremia is rare with PB19; however, this infection can progress to life-threatening conditions. In our extensive review of the literature, only six reports of septic shock were associated with PB19. (<xref ref-type="bibr" rid="B10">Ferraz et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B2">Bailey, 2006</xref>; <xref ref-type="bibr" rid="B18">Kaur et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B30">Panicker et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B13">Garc&#xed;a-Salido et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B21">Kuriyama et&#xa0;al., 2016</xref>)</p>
<p>The pathogenesis of severe septic shock associated with PB19 is not well understood. PB19 targets erythroid progenitors in the bone marrow by binding to glycosphingolipid globoside, leading to large receptor-induced structural changes triggering cell death either by lysis or by apoptosis mediated by the non-structural 1 protein (NS 1) (<xref ref-type="bibr" rid="B33">Rogo et&#xa0;al., 2014</xref>). Transactivation of the IL-6 gene by NS1 may represent a common pathway to parvovirus B19-induced tissue damage in many different sites of the body (<xref ref-type="bibr" rid="B28">Mitchell, 2002</xref>). The viral particles or the cellular debris from red blood cell destruction could have initiated the systemic inflammatory activation, resulting in sepsis in this case.</p>
<p>We report the first case of severe septic shock associated with PB19 infection after cardiac surgery, which was successfully treated by immunoglobulin. A review of literature on this situation is also performed.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Case presentation</title>
<p>Our patient is a 50-year-old Chinese woman. She was hospitalized for exertional dyspnoea and easily induced fatigue that she experienced over the 17 years prior to the admission. The patient had a prior diagnosis of rheumatic valvular disease. At admission, the chest X-ray showed cardiac enlargement. Cardiac sonography revealed severe aortic valve disease (stenosis and regurgitation) and mitral stenosis. Therefore, double metal valve replacement, including the aortic valve and the mitral valve, was suggested and performed. After the surgical intervention, a transesophageal echocardiogram revealed no residual valvular event; however, hypotension and a rapid pulse rate were still observed after the operation (lowest blood pressure 88/44 mmHg; heart rate 112 beats per minute). Through the use of vasoactive medications, fluid resuscitation, anti-infectives and other treatments, the patient was transferred to the department of cardiac surgery in good condition on PD 7.</p>
<p>Unfortunately, the patient&#x2019;s temperature increased to 38.5&#xb0;C in the evening of PD 30, and she had shaking chills, diarrhoea, a heart rate of 138 per minute, a respiratory rate of 32 per minute, and a blood pressure of 130/62 mmHg with norepinephrine (0.02 &#xb5;g/kg/min) infusion. An erythematous rash was present over the trunk and extremities. Persistent fever and diarrhoea developed with persistent circulatory failure, despite empiric antibiotic treatment (piperacillin-tazobactam 4.5&#xa0;g iv q8 h), which was given after blood culture, stool culture and sputum culture sampling.</p>
<p>Due to further deterioration of the patient&#x2019;s circulation, accompanied by continuous fever (up to 41&#xb0;C), progressive decrease of haemoglobin, anuria and a worsening of the rash on her limbs, the patient was transferred to the SICU for continuous treatment on PD 32. On the physical examination, the blood pressure was 96/70 mmHg with norepinephrine (0.08 &#xb5;g/kg/min), temperature 37.3&#xb0;C, respiratory rate of 30 per minute, oxygen saturation 98% with nasal cannula of oxygen-therapy at 4 litres-min, the heart rate was 140 bpm, and a metal sound of the valve was noted at the left-sternal border without murmur, pulmonary crackles, or oedema in the lower extremities. An erythematous maculopapular rash was distributed on the arms and lower legs but did not involve the trunk (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). There were erythematous macules and papules, approximately 1 to 5&#xa0;mm in diameter, which did not blanch on pressure. Laboratory data included a white blood cell count of 13.53 &#xd7; 109/L with 93.3% neutrophils and 4.9% lymphocytes, a platelet count of 174 &#xd7; 109/L, haemoglobin of 82 g/L, blood lactate of 2.1 mmol/L, hypersensitive C-reactive protein (Hs-CRP) of 228.09 mg/L, procalcitonin (PCT) of 332.00 ng/ml, B-type natriuretic peptide of 71.50 pg/ml, blood glucose of 12.11 mmol/L, and arterial blood lactate of 4.2 mmol/L. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), and blood urea nitrogen (BUN) were variably elevated (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Although the patient had a normal number of B lymphocytes and natural killer cells, the immunologic condition showed decreased counts of CD4+ and CD8+ lymphocytes (CD4+: 135/&#xb5;l, CD8+: 120/&#xb5;l).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Evolution of the rash. <bold>(A)</bold> The early lesions were erythematous macules or papules approximately 1 to 5&#xa0;mm in diameter that did not blanch on pressure. The erythematous maculopapular rash was mostly distributed on the arms and lower legs but was less distributed in the trunk. <bold>(B)</bold> The vesicles were pale or yellowish from serous fluid matter. The vesicles slowly become enlarged and ruptured, leaving exuding areas. <bold>(C)</bold> Skin healing with desquamation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-13-1064760-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>The variations trend of laboratory data.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left"/>
<th valign="middle" align="center">unit</th>
<th valign="middle" align="center">On admission</th>
<th valign="middle" align="center">PD* 29</th>
<th valign="middle" align="center">PD 30&#x266f;</th>
<th valign="middle" align="center">PD 31</th>
<th valign="middle" align="center">PD 32</th>
<th valign="middle" align="center">PD 33</th>
<th valign="middle" align="center">PD 34</th>
<th valign="middle" align="center">PD 35</th>
<th valign="middle" align="center">PD 36</th>
<th valign="middle" align="center">PD 37</th>
<th valign="middle" align="center">PD 38</th>
<th valign="middle" align="center">PD 39</th>
<th valign="middle" align="center">reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">White blood cell</td>
<td valign="middle" align="left">10^9/L</td>
<td valign="middle" align="center">7.070</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">9.630</td>
<td valign="middle" align="center">11.610</td>
<td valign="middle" align="center">6.350</td>
<td valign="middle" align="center">11.370</td>
<td valign="middle" align="center">11.620</td>
<td valign="middle" align="center">7.450</td>
<td valign="middle" align="center">8.410</td>
<td valign="middle" align="center">7.660</td>
<td valign="middle" align="center">7.200</td>
<td valign="middle" align="center">3.50-9.50</td>
</tr>
<tr>
<td valign="middle" align="left">Neutrophil</td>
<td valign="middle" align="left">10^9/L</td>
<td valign="middle" align="center">5.182</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">7.271</td>
<td valign="middle" align="center">11.146</td>
<td valign="middle" align="center">5.632</td>
<td valign="middle" align="center">9.994</td>
<td valign="middle" align="center">11.027</td>
<td valign="middle" align="center">6.541</td>
<td valign="middle" align="center">7.207</td>
<td valign="middle" align="center">6.787</td>
<td valign="middle" align="center">5.530</td>
<td valign="middle" align="center">1.80-6.30</td>
</tr>
<tr>
<td valign="middle" align="left">Neutrophil ratio</td>
<td valign="middle" align="left">%</td>
<td valign="middle" align="center">73.3</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">75.5</td>
<td valign="middle" align="center">96.0</td>
<td valign="middle" align="center">88.7</td>
<td valign="middle" align="center">87.9</td>
<td valign="middle" align="center">94.9</td>
<td valign="middle" align="center">87.8</td>
<td valign="middle" align="center">85.7</td>
<td valign="middle" align="center">88.6</td>
<td valign="middle" align="center">76.8</td>
<td valign="middle" align="center">40.0-75.0</td>
</tr>
<tr>
<td valign="middle" align="left">Lymphocyte</td>
<td valign="middle" align="left">10^9/L</td>
<td valign="middle" align="center">1.188</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">1.348</td>
<td valign="middle" align="center">0.302</td>
<td valign="middle" align="center">0.508</td>
<td valign="middle" align="center">0.955</td>
<td valign="middle" align="center">0.256</td>
<td valign="middle" align="center">0.410</td>
<td valign="middle" align="center">0.690</td>
<td valign="middle" align="center">0.421</td>
<td valign="middle" align="center">0.482</td>
<td valign="middle" align="center">1.10-3.20</td>
</tr>
<tr>
<td valign="middle" align="left">Hemoglobin</td>
<td valign="middle" align="left">g/L</td>
<td valign="middle" align="center">114</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">80</td>
<td valign="middle" align="center">79</td>
<td valign="middle" align="center">64</td>
<td valign="middle" align="center">62</td>
<td valign="middle" align="center">70</td>
<td valign="middle" align="center">66</td>
<td valign="middle" align="center">74</td>
<td valign="middle" align="center">77</td>
<td valign="middle" align="center">85</td>
<td valign="middle" align="center">115-150</td>
</tr>
<tr>
<td valign="middle" align="left">Platelets</td>
<td valign="middle" align="left">10^9/L</td>
<td valign="middle" align="center">174</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">343</td>
<td valign="middle" align="center">193</td>
<td valign="middle" align="center">71</td>
<td valign="middle" align="center">56</td>
<td valign="middle" align="center">36</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">54</td>
<td valign="middle" align="center">101-320</td>
</tr>
<tr>
<td valign="middle" align="left">PCT</td>
<td valign="middle" align="left">ng/mL</td>
<td valign="middle" align="center">0.03</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">0.27</td>
<td valign="middle" align="center">330.40</td>
<td valign="middle" align="center">160.00</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">43.30</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">8.74</td>
<td valign="middle" align="center">0-0.05</td>
</tr>
<tr>
<td valign="middle" align="left">Hs-CRP</td>
<td valign="middle" align="left">mg/L</td>
<td valign="middle" align="center">6.41</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center"/>
<td valign="middle" align="center">32.36</td>
<td valign="middle" align="center">151.76</td>
<td valign="middle" align="center">208.39</td>
<td valign="middle" align="center">193.01</td>
<td valign="middle" align="center">100.35</td>
<td valign="middle" align="center">120.93</td>
<td valign="middle" align="center">77.89</td>
<td valign="middle" align="center">51.11</td>
<td valign="middle" align="center">29.34</td>
<td valign="middle" align="center">0-5.00</td>
</tr>
<tr>
<td valign="middle" align="left">Total bilirubin</td>
<td valign="middle" align="left">umol/l</td>
<td valign="middle" align="center">17.7</td>
<td valign="middle" align="center">11.2</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">11.2</td>
<td valign="middle" align="center">9.9</td>
<td valign="middle" align="center">18.3</td>
<td valign="middle" align="center">25.7</td>
<td valign="middle" align="center">20.2</td>
<td valign="middle" align="center">15.3</td>
<td valign="middle" align="center">13.4</td>
<td valign="middle" align="center">17.1</td>
<td valign="middle" align="center">0.0-21.0</td>
</tr>
<tr>
<td valign="middle" align="left">Direct bilirubin</td>
<td valign="middle" align="left">umol/l</td>
<td valign="middle" align="center">5.3</td>
<td valign="middle" align="center">3.6</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">1.9</td>
<td valign="middle" align="center">8.4</td>
<td valign="middle" align="center">5.8</td>
<td valign="middle" align="center">9.7</td>
<td valign="middle" align="center">15.1</td>
<td valign="middle" align="center">11.5</td>
<td valign="middle" align="center">8.4</td>
<td valign="middle" align="center">8.9</td>
<td valign="middle" align="center">6.6</td>
<td valign="middle" align="center">0.0-8.0</td>
</tr>
<tr>
<td valign="middle" align="left">AST</td>
<td valign="middle" align="left">U/L</td>
<td valign="middle" align="center">61</td>
<td valign="middle" align="center">26</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">171</td>
<td valign="middle" align="center">132</td>
<td valign="middle" align="center">133</td>
<td valign="middle" align="center">185</td>
<td valign="middle" align="center">138</td>
<td valign="middle" align="center">64</td>
<td valign="middle" align="center">29</td>
<td valign="middle" align="center">29</td>
<td valign="middle" align="center">13-35</td>
</tr>
<tr>
<td valign="middle" align="left">ALT</td>
<td valign="middle" align="left">U/L</td>
<td valign="middle" align="center">106</td>
<td valign="middle" align="center">22</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">57</td>
<td valign="middle" align="center">59</td>
<td valign="middle" align="center">61</td>
<td valign="middle" align="center">79</td>
<td valign="middle" align="center">69</td>
<td valign="middle" align="center">52</td>
<td valign="middle" align="center">37</td>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">7-40</td>
</tr>
<tr>
<td valign="middle" align="left">Cr</td>
<td valign="middle" align="left">umol/l</td>
<td valign="middle" align="center">58.6</td>
<td valign="middle" align="center">78.0</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">87.0</td>
<td valign="middle" align="center">338.0</td>
<td valign="middle" align="center">320.0</td>
<td valign="middle" align="center">271.0</td>
<td valign="middle" align="center">208.0</td>
<td valign="middle" align="center">211.0</td>
<td valign="middle" align="center">316.0</td>
<td valign="middle" align="center">364.0</td>
<td valign="middle" align="center">374.0</td>
<td valign="middle" align="center">49.0-82.0</td>
</tr>
<tr>
<td valign="middle" align="left">BUN</td>
<td valign="middle" align="left">mmol/l</td>
<td valign="middle" align="center">5.55</td>
<td valign="middle" align="center">8.10</td>
<td valign="middle" align="center"/>
<td valign="middle" align="center">7.80</td>
<td valign="middle" align="center">15.10</td>
<td valign="middle" align="center">13.80</td>
<td valign="middle" align="center">13.00</td>
<td valign="middle" align="center">12.10</td>
<td valign="middle" align="center">13.30</td>
<td valign="middle" align="center">31.70</td>
<td valign="middle" align="center">37.70</td>
<td valign="middle" align="center">38.00</td>
<td valign="middle" align="center">2.60-7.50</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>*PD, postoperative day; &#x266f; The patient suffered the symptoms of unknown infection at in the evening of PD 30, like fever, shaking chill, diarrhea subsequently.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Bedside transthoracic echocardiography showed that the patient&#x2019;s right ventricle was in normal size and functioned well, and the patient had enlargement of the left atrium and left ventricle (LA: 50&#xa0;mm; LAD: 53&#xa0;mm). The LVEF was 55%, without pericardial effusion. No mechanical prosthetic valve dysfunction was observed. The electrocardiograph showed sinus tachycardia without abnormal ST-T.</p>
<p>The detection of mNGS in the blister fluid and serum from this patient was performed. Empiric antibiotic administration (vancomycin, meropenem and caspofungin) was administered. When the patient&#x2019;s haemodynamic status gradually worsened, norepinephrine (0.72 &#xb5;g/kg/min), terlipressin (0.02 &#xb5;g/kg/min) and cortisol were given due to the emergence of the situation resulting from haemodynamic instability. To decrease the internal milieu disorder in time and clear the various inflammatory mediums efficiently, continuous renal replacement therapy plus hemoperfusion (HA380) was performed. To identify the pathogen as soon as possible, blood culture, stool culture and sputum culture were obtained before antimicrobial administration was continued.</p>
<p>Interestingly, vesicles appeared on PD 33 and were pale or yellowish from serous fluid matter. The vesicles slowly became enlarged and ruptured, leaving exuding areas (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>).</p>
<p>After transfer to our department, PB19-specific nucleic acids were detected in mNGS samples of the patient&#x2019;s blister fluid and serum, and the fluids were negative for other viral, fungal, or bacterial nucleic acids (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). Confirmatory examination showed that PB19 IgM and IgG in serum both were positive (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). We checked the antefebrile serum antibody, when PB19 IgM and IgG were both positive after fever. Interestingly, confirmatory examination of antefebrile serum antibody showed that PB19 IgG in serum was positive, while IgM was negative (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). All of the cultures, including blood, stool and sputum, obtained negative results. The serology of HIV, HBV, HCV, EBV, CMV, <italic>Toxoplasma gondii</italic> and <italic>Mycoplasma pneumoniae</italic> were all negative. Laboratory investigations revealed a negative serum (1,3)-&#x3b2;-D-glucan test and galactomannan antigen test. The hypocomplementemia complement component 3 concentration was 0.44 [normal 0.9&#x2013;1.8] g/L; the complement component 4 concentration was 0.08 [normal 0.100&#x2013;0.400] g/L). Serologic testing showed elevated immunoglobulin E (408.00 [normal 0.00&#x2013;100.00] IU/mL), but the levels of the other immunoglobulins were normal. The autoimmune antibody profile and pemphigus antibodies were within normal limits. Based on these clinical findings, a multidisciplinary consultation was organized. We substituted vancomycin, meropenem and caspofungin with 4.5&#xa0;g of intravenous piperacillin-tazobactam every 8 hours. On this basis, this patient was treated with intravenous immunoglobulin (IVIG) 400 mg/kg/d for 5 consecutive days and methylprednisolone 1 mg/kg/d. Topical measures were performed to prevent secondary infections and facilitate the healing of the blisters. After five days of the combined treatment, no further fever or abdominal discomfort was noted, and the patient&#x2019;s circulation gradually stabilized without vasoactive medications (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>) (<xref ref-type="bibr" rid="B12">Gaies et&#xa0;al., 2010</xref>). The skin healed with desquamation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Human Parvovirus B19-specific nucleic acids were detected in mNGS samples of serum and blister fluid. Sequence distribution map: This part only shows the sequence distribution map of species with &#x2265;3 nonrepeat specific sequences detected. <bold>(A)</bold> Serum samples. The total length covered on the genome is 3623 bp, the coverage is 64.7427%, and the average depth is 1.65X. <bold>(B)</bold> Blister fluid samples. The total length covered on the genome is 1059 bp, the coverage is 18.9242%, and the average depth is 1.18X.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-13-1064760-g002.tif"/>
</fig>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>The changes of IgM and IgG in serum.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="left">
</th>
<th valign="bottom" align="center">IgM</th>
<th valign="bottom" align="center">IgG</th>
<th valign="bottom" align="center">Normal range</th>
<th valign="bottom" align="center">test method</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="left">PD 28#</td>
<td valign="bottom" align="center">
<bold>-</bold>
</td>
<td valign="bottom" align="center">
<bold>+</bold>
</td>
<td valign="bottom" align="center">
<bold>-</bold>
</td>
<td valign="bottom" align="center">ELISA</td>
</tr>
<tr>
<td valign="bottom" align="left">PD 33*</td>
<td valign="bottom" align="center">
<bold>+</bold>
</td>
<td valign="bottom" align="center">
<bold>+</bold>
</td>
<td valign="bottom" align="center">
<bold>-</bold>
</td>
<td valign="bottom" align="center">ELISA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p># 28 days after operation; *33 days after operation and 4 days after fever.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>The trend of the mean VIS. #PD, postoperative day; *VIS, Vasoactive&#x2013;Inotrope Scoring. VIS= dopamine dose (&#xb5;g/kg/min) + dobutamine dose (&#xb5;g/kg/min) + 100* epinephrine dose (&#xb5;g/kg/min) + 10*milrinone dose (&#xb5;g/kg/min) + 10,000* vasopressin dose (U/kg/min) + 100* norepinephrine dose (&#xb5;g/kg/min). The hourly doses of the following inotropic and vasoactive medications were recorded every day: dopamine, dobutamine, epinephrine, norepinephrine, milrinone, and vasopressin. The mean VIS was obtained by averaging the hourly scores during 24-hr periods.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-13-1064760-g003.tif"/>
</fig>
</sec>
<sec id="s3" sec-type="discussion">
<label>3</label>
<title>Discussion</title>
<p>PB19 infection is usually a self-limited disease (<xref ref-type="bibr" rid="B22">Landry, 2016</xref>). Due to the difficulty in isolating the virus by conventional cell culture, the diagnosis of PB19 relies on serology and DNA detection (<xref ref-type="bibr" rid="B42">Young and Brown, 2004</xref>; <xref ref-type="bibr" rid="B22">Landry, 2016</xref>). The evidence supporting acute PB19 infection in our case was derived from the presence of PB19-specific nucleic acids (in serum and blister fluid), positive serum PB19 IgM and no other proven infection (<xref ref-type="bibr" rid="B27">Miron et&#xa0;al., 2006</xref>; <xref ref-type="bibr" rid="B22">Landry, 2016</xref>). Although PB19 acute infections of children can result in EI, up to 50% infection is asymptomatic. A prodromal nonspecific illness consisting of fever, chills, headache, malaise, and myalgias, coinciding with PB19 viremia, can occur, followed by a typical &#x201c;slapped cheek&#x201d; facial rash and a lacy, reticular erythematous rash on the trunk and extremities coincident with the immune response. (<xref ref-type="bibr" rid="B22">Landry, 2016</xref>) But in adult patients, the typical EI rash is much less common and primary PB19 infection is associated with polymorphous skin manifestations with four predominant, sometimes overlapping, patterns:exanthema, which was reticulated and annular in some cases; the gloves-and-socks pattern; the periflexural pattern; and palpable purpura. Concomitantly, the rash predominated on the legs, trunk, and arms, with a lower frequency of facial involvement. (<xref ref-type="bibr" rid="B8">Drago et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B24">Mage et&#xa0;al., 2014</xref>). Likewise, at an earlier stage of the disease, the gloves-and-socks pattern and palpable purpura were observed on the lower legs, trunk, and arms without pruritus in our case. And these lesions gradually became erythematous with vesiculation.</p>
<p>Septic shock from viremia rarely occurs with PB19; however, this infection can progress to life-threatening conditions, as seen in our patient. This is the first report on severe septic shock associated with PB19 infection after cardiac surgery. In our extensive review of the literature, only six reports of septic shock were associated with PB19 (<xref ref-type="bibr" rid="B10">Ferraz et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B2">Bailey, 2006</xref>; <xref ref-type="bibr" rid="B18">Kaur et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B30">Panicker et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B13">Garc&#xed;a-Salido et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B21">Kuriyama et&#xa0;al., 2016</xref>). It is noteworthy that there was only one published case in which the patient had sickle cell disease, which is associated with an increased risk of serious and life-threatening infections (<xref ref-type="bibr" rid="B30">Panicker et&#xa0;al., 2011</xref>). Most of the patients reported in the case reports were previously healthy, including 3 adult women and 7-year-olds. In contrast, the reported patient&#x2019;s immunity level was low at the time of hospitalization after cardiac surgery, which might be due to cardiac surgery injury, CPB, blood loss and malnutrition (<xref ref-type="bibr" rid="B1">Angele and Faist, 2002</xref>; <xref ref-type="bibr" rid="B14">Gaudriot et&#xa0;al., 2015</xref>; <xref ref-type="bibr" rid="B3">Candela et&#xa0;al., 2021</xref>). A previous study showed that the bactericidal activity of neutrophil bactericidal agents against <italic>Staphylococcus aureus</italic> was decreased after cardiac surgery (<xref ref-type="bibr" rid="B25">Mekontso-Dessap et&#xa0;al., 2005</xref>). <xref ref-type="bibr" rid="B7">Chalk et&#xa0;al. (2013)</xref> have also reported dysfunction of pulmonary macrophages, and patients have strong systemic immune depression after CPB. Moreover, <xref ref-type="bibr" rid="B39">Torrance et&#xa0;al. (2018)</xref> reported an association between monocyte dysfunction and major surgery in a study, consisting of 119 participants undergoing the elective gastro-intestinal surgery. As a result, immunodepression increased the susceptibility to infection in surgical patients (<xref ref-type="bibr" rid="B1">Angele and Faist, 2002</xref>; <xref ref-type="bibr" rid="B41">Volk, 2002</xref>). Findings from the Cardiac Surgical Intensive Care Unit records, which were conducted among 6864 patients after cardiac surgery in 2013-2014, indicate that 4.6% of the patients developed nosocomial infections, including 24 (7.5%) that are consistent with the diagnosis of bloodstream infection (<xref ref-type="bibr" rid="B34">Sahu et&#xa0;al., 2016</xref>). Klebsiella, Pseudomonas, Enterobacter, <italic>Escherichia coli</italic>, Acinetobacter, and Staphylococcus were the most frequent pathogens isolated from patients with bloodstream infections (<xref ref-type="bibr" rid="B34">Sahu et&#xa0;al., 2016</xref>).</p>
<p>However, the pathogenesis of severe septic shock associated with PB19 is not well understood. PB19 targets erythroid progenitors in the bone marrow by binding to glycosphingolipid globoside, leading to large receptor-induced structural changes triggering cell death either by lysis or by apoptosis mediated by the non-structural 1 protein (NS 1) (<xref ref-type="bibr" rid="B33">Rogo et&#xa0;al., 2014</xref>). Transactivation of the IL-6 gene by NS1 may represent a common pathway to parvovirus B19-induced tissue damage in many different sites of the body (<xref ref-type="bibr" rid="B28">Mitchell, 2002</xref>).</p>
<p>Despite the patient&#x2019;s immunocompromised status, it remains unclear how the reported patient became infected. As previously reported in the literature, in compromised hosts, B19 infection can be acquired <italic>via</italic> the respiratory route, from endogenous reactivation, or from blood products (<xref ref-type="bibr" rid="B22">Landry, 2016</xref>). No sign revealing cross infections was found in our case, although nosocomial outbreaks of PB19 infection have been reported (<xref ref-type="bibr" rid="B31">Pillay et&#xa0;al., 1992</xref>; <xref ref-type="bibr" rid="B36">Seng et&#xa0;al., 1994</xref>; <xref ref-type="bibr" rid="B29">Miyamoto et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B23">Lui et&#xa0;al., 2001</xref>). Strong evidence reveals that PB19 DNA has been detected in bone marrow samples, peripheral blood, synovium, myocardium, and skin for months and even years after the primary infection and the resolution of symptoms of normal hosts (<xref ref-type="bibr" rid="B5">Cassinotti et&#xa0;al., 1993</xref>; <xref ref-type="bibr" rid="B20">Kerr et&#xa0;al., 1995</xref>; <xref ref-type="bibr" rid="B4">Cassinotti et&#xa0;al., 1997</xref>; <xref ref-type="bibr" rid="B6">Cassinotti and Siegl, 2000</xref>; <xref ref-type="bibr" rid="B15">Heegaard et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B17">Hokynar et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B37">S&#xf6;derlund-Venermo et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B35">Schenk et&#xa0;al., 2009</xref>). In addition to <italic>de novo</italic> infections, viruses go into latency periods and can be reactivated in both immunosuppressed and immunocompetent critically ill patients (<xref ref-type="bibr" rid="B22">Landry, 2016</xref>; <xref ref-type="bibr" rid="B11">Fragkou et&#xa0;al., 2021</xref>). The infection in this patient may be explained by secondary reactivation of PB19 due to the patient&#x2019;s immunocompromised status. The evidence supporting this hypothesis in our case was derived from the positive serum PB19 IgG, while IgM was negative on PD28 (2 days before fever). IgG is a protective antibody, which indicates the past infection. Additionally, the transmission of symptomatic PB19 infection by blood products used during surgery, such as fibrin sealant, has been reported previously (<xref ref-type="bibr" rid="B16">Hino et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B9">Enoki et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B19">Kawamura et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B40">Tournoux et&#xa0;al., 2004</xref>). The International Hemovigilance Network collected aggregate data on suspected transfusion-transmitted infections for 2013-2016 from member national hemovigilance systems. In one patient, there was clinical suspicion of PB19 infection obtained by blood transfusion (<xref ref-type="bibr" rid="B32">Politis et&#xa0;al., 2019</xref>).</p>
<p>Unfortunately, no antiviral therapy is available to treat PB19 infection (<xref ref-type="bibr" rid="B33">Rogo et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B22">Landry, 2016</xref>; <xref ref-type="bibr" rid="B11">Fragkou et&#xa0;al., 2021</xref>). The treatment of choice mainly includes red-cell transfusion, adjustment in medications to restore or improve the patient&#x2019;s immune system, and administration of IVIG (<xref ref-type="bibr" rid="B38">Szenborn, 2011</xref>; <xref ref-type="bibr" rid="B22">Landry, 2016)</xref>. A regimen of 400 mg/kg/day for five to ten days has been suggested (<xref ref-type="bibr" rid="B42">Young and Brown, 2004</xref>). However, the efficiency of IVIG in severe septic shock patients is unclear. Because the patient&#x2019;s circulation gradually stabilized with clinical improvements after treatments, we believe that IVIG was beneficial in this case.</p>
<p>In our case, there is a limitation, which should be mentioned. Serum procalcitonin was markedly elevated, and there might be other unrecognized infections, although mNGS, all of the cultures, including blood, stool and sputum, and serology of HIV, HBV, HCV, EBV, CMV, Toxoplasma gondii and Mycoplasma pneumoniae obtained negative results except PB19.</p>
<p>The case presented provides evidence that PB19 may be an unrecognized cause of septic shock, rash, fever of unknown origin or multiple systemic signs and symptoms, especially in immunosuppressed and immunocompetent critically ill patients. Investigations for viral aetiology are needed.</p>
</sec>
<sec id="s4" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s5" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>YPW designed the study. CLX, XXW, and YPW contributed to collection and collation the clinical data. CLX and YKW contributed to extract data from literature and manuscript writing. TLL, XMT, XQZ, XBH and YW contributed to manuscript revisions and approved the final manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>Funding was provided by the Key Research and Development Project of Science and Technology of Sichuan Province (Grant no. 21ZDYF4270), Sichuan Science and Technology Department (Grant no. 2021YFS0373).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors wish to thank the patient for participating in this study.</p>
</ack>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angele</surname> <given-names>M. K.</given-names>
</name>
<name>
<surname>Faist</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Clinical review: immunodepression in the surgical patient and increased susceptibility to infection</article-title>. <source>Crit. Care</source> <volume>6</volume>, <fpage>298</fpage>&#x2013;<lpage>305</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/cc1514</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname> <given-names>J. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Parvovirus B19 presenting with severe sepsis in a previously healthy 25-year-old female</article-title>. <source>J. Am. Board Fam. Med.</source> <volume>19</volume>, <fpage>317</fpage>&#x2013;<lpage>319</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3122/jabfm.19.3.317</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Candela</surname> <given-names>C. G.</given-names>
</name>
<name>
<surname>Milla</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Lozano</surname> <given-names>E. C.</given-names>
</name>
<name>
<surname>Di Martino</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Alcolea</surname> <given-names>N. G.</given-names>
</name>
<name>
<surname>Rold&#xe1;n</surname> <given-names>J. O.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>De la evidencia y algoritmo adaptado immunonutrition in fast-track surgical patients - evidence review and adapted algorithm</article-title>. <source>Nutr. Hosp.</source> <volume>38</volume>, <fpage>601</fpage>&#x2013;<lpage>6021</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.20960/nh.03405</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassinotti</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Burtonboy</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Fopp</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Siegl</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Evidence for persistence of human parvovirus B19 DNA in bone marrow</article-title>. <source>J. Med. Virol.</source> <volume>53</volume>, <fpage>229</fpage>&#x2013;<lpage>232</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/(SICI)1096-9071(199711)53:3&lt;229::AID-JMV8&gt;3.0.CO;2-A</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassinotti</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Schultze</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Schlageter</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Chevili</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Siegl</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source> <volume>12</volume>, <fpage>701</fpage>&#x2013;<lpage>704</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/bf02009384</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassinotti</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Siegl</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>). quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source> <volume>19</volume>, <fpage>886</fpage>&#x2013;<lpage>887</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s100960000384</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chalk</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Meisel</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Spies</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Volk</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Thuenemann</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Linneweber</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Dysfunction of alveolar macrophages after cardiac surgery and postoperative pneumonia?&#x2013;an observational study</article-title>. <source>Crit. Care</source> <volume>17</volume>, <fpage>R285</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/cc13148</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drago</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Ciccarese</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Rebora</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Exanthems associated with parvovirus B19 infection in adults</article-title>. <source>J. Am. Acad. Dermatol.</source> <volume>71</volume>, <fpage>1256</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaad.2014.07.063</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enoki</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Higashi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Oohata</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>A case of acute erythroblastic anemia due to infection with human parvovirus B19 after coronary artery bypass grafting</article-title>. <source>Kyobu Geka</source> <volume>55</volume>, <fpage>116</fpage>&#x2013;<lpage>119</lpage>.</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraz</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Cunha</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Mota</surname> <given-names>T. C.</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Sim&#xf5;es</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Aparicio</surname> <given-names>J. M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Acute respiratory distress syndrome in a child with human parvovirus B19 infection</article-title>. <source>Pediatr. Infect. Dis. J.</source> <volume>24</volume>, <fpage>1009</fpage>&#x2013;<lpage>1010</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.inf.0000183768.84890.ae</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fragkou</surname> <given-names>P. C.</given-names>
</name>
<name>
<surname>Moschopoulos</surname> <given-names>C. D.</given-names>
</name>
<name>
<surname>Karofylakis</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Kelesidis</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Tsiodras</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Update in viral infections in the intensive care unit</article-title>. <source>Front. Med.</source> <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmed.2021.575580</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaies</surname> <given-names>M. G.</given-names>
</name>
<name>
<surname>Gurney</surname> <given-names>J. G.</given-names>
</name>
<name>
<surname>Yen</surname> <given-names>A. H.</given-names>
</name>
<name>
<surname>Napoli</surname> <given-names>M. L.</given-names>
</name>
<name>
<surname>Gajarski</surname> <given-names>R. J.</given-names>
</name>
<name>
<surname>Ohye</surname> <given-names>R. G.</given-names>
</name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass</article-title>. <source>Pediatr. Crit. Care Med.</source> <volume>11</volume>, <fpage>234</fpage>&#x2013;<lpage>238</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/PCC.0b013e3181b806fc</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a-Salido</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Serrano</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Iglesias-Bouzas</surname> <given-names>M. I.</given-names>
</name>
<name>
<surname>Blanco-Iglesias</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Hern&#xe1;ndez-Mart&#xed;n</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Casado-Flores</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Systemic inflammatory response syndrome and septic shock due to parvovirus B19 in a healthy child</article-title>. <source>An. Pediatr. (Barc)</source> <volume>80</volume>, <fpage>269</fpage>&#x2013;<lpage>270</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.anpedi.2013.09.020</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaudriot</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Uhel</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Gregoire</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Gacouin</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Biedermann</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Roisne</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Immune dysfunction after cardiac surgery with cardiopulmonary bypass: Beneficial effects of maintaining mechanical ventilation</article-title>. <source>Shock</source> <volume>44</volume>, <fpage>228</fpage>&#x2013;<lpage>233</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/shk.0000000000000416</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heegaard</surname> <given-names>E. D.</given-names>
</name>
<name>
<surname>Petersen</surname> <given-names>B. L.</given-names>
</name>
<name>
<surname>Heilmann</surname> <given-names>C. J.</given-names>
</name>
<name>
<surname>Hornsleth</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals</article-title>. <source>J. Clin. Microbiol.</source> <volume>40</volume>, <fpage>933</fpage>&#x2013;<lpage>936</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/jcm.40.3.933-936.2002</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hino</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ishiko</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Honda</surname> <given-names>K. I.</given-names>
</name>
<name>
<surname>Yamane</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Ohta</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Takubo</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery</article-title>. <source>Br. J. Haematol.</source> <volume>108</volume>, <fpage>194</fpage>&#x2013;<lpage>195</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1365-2141.2000.01818.x</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hokynar</surname> <given-names>K.</given-names>
</name>
<name>
<surname>S&#xf6;derlund-Venermo</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Pesonen</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ranki</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Kiviluoto</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Partio</surname> <given-names>E. K.</given-names>
</name>
<etal/>
</person-group>. (<year>2002</year>). <article-title>A new parvovirus genotype persistent in human skin</article-title>. <source>Virology</source> <volume>302</volume>, <fpage>224</fpage>&#x2013;<lpage>228</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/viro.2002.1673</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaur</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Loganathan</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Schliep</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Kanna</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Sivapalan</surname> <given-names>V.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>An unusual case of toxic shock syndrome: A case report and review of viral etiologic agents</article-title>. <source>Infect. Dis. Clin. Pract.</source> <volume>19</volume>, <fpage>428</fpage>&#x2013;<lpage>430</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/IPC.0b013e31820a52cc</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawamura</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sawafuji</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Watanabe</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Horinouchi</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kobayashi</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery</article-title>. <source>Ann. Thorac. Surg.</source> <volume>73</volume>, <fpage>1098</fpage>&#x2013;<lpage>1100</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0003-4975(02)03415-x</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname> <given-names>J. R.</given-names>
</name>
<name>
<surname>Curran</surname> <given-names>M. D.</given-names>
</name>
<name>
<surname>Moore</surname> <given-names>J. E.</given-names>
</name>
<name>
<surname>Murphy</surname> <given-names>P. G.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Parvovirus B19 infection&#x2013;persistence and genetic variation</article-title>. <source>Scand. J. Infect. Dis.</source> <volume>27</volume>, <fpage>551</fpage>&#x2013;<lpage>557</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3109/00365549509047066</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuriyama</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Tabata</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kitaguchi</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Vasodilatory shock due to parvovirus B19 infection</article-title>. <source>Crit. Care Med.</source> <volume>44</volume>, <fpage>518</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.ccm.0000510445.57804.d5</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landry</surname> <given-names>M. L.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Parvovirus B19</article-title>. <source>Microbiol. Spectr.</source> <volume>4</volume>, <fpage>4.3.34</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/microbiolspec.DMIH2-0008-2015</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lui</surname> <given-names>S. L.</given-names>
</name>
<name>
<surname>Luk</surname> <given-names>W. K.</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>C. Y.</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>T. M.</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>K. N.</given-names>
</name>
<name>
<surname>Peiris</surname> <given-names>J. S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit</article-title>. <source>Transplantation</source> <volume>71</volume>, <fpage>59</fpage>&#x2013;<lpage>64</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00007890-200101150-00010</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mage</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Lipsker</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Barbarot</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Bessis</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Chosidow</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Del Giudice</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults</article-title>. <source>J. Am. Acad. Dermatol.</source> <volume>71</volume>, <fpage>62</fpage>&#x2013;<lpage>69</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaad.2014.02.044</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mekontso-Dessap</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Honor&#xe9;</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kirsch</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Plonquet</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Fernandez</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Touqui</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Blood neutrophil bactericidal activity against methicillin-resistant and methicillin-sensitive staphylococcus aureus during cardiac surgery</article-title>. <source>Shock</source> <volume>24</volume>, <fpage>109</fpage>&#x2013;<lpage>113</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.shk.0000171871.50524.81</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname> <given-names>O.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Parvovirus B19 and autoimmune diseases</article-title>. <source>Joint Bone Spine</source> <volume>70</volume>, <fpage>6</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1297-319x(02)00004-0</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miron</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Luder</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Horovitz</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Izkovitz</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Shizgreen</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Ben David</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>Acute human parvovirus b-19 infection in hospitalized children: A serologic and molecular survey</article-title>. <source>Pediatr. Infect. Dis. J.</source> <volume>25</volume>, <fpage>898</fpage>&#x2013;<lpage>901</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/01.inf.0000237865.01251.d2</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname> <given-names>L. A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections</article-title>? <source>J. Med. Virol.</source> <volume>67</volume>, <fpage>267</fpage>&#x2013;<lpage>274</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.2217</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Ogami</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Mori</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Akimoto</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Terashita</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>Outbreak of human parvovirus B19 in hospital workers</article-title>. <source>J. Hosp. Infect.</source> <volume>45</volume>, <fpage>238</fpage>&#x2013;<lpage>241</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1053/jhin.2000.0771</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panicker</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>R. G.</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>S. D.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Coinfection with parvovirus B19 and epstein barr virus in an adolescent with sickle cell disease manifesting as septic shock</article-title>. <source>Blood</source> <volume>118</volume>, <elocation-id>4854</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.V118.21.4854.4854</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillay</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Patou</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Hurt</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kibbler</surname> <given-names>C. C.</given-names>
</name>
<name>
<surname>Griffiths</surname> <given-names>P. D.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Parvovirus B19 outbreak in a children's ward</article-title>. <source>Lancet</source> <volume>339</volume>, <fpage>107</fpage>&#x2013;<lpage>109</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0140-6736(92)91009-w</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Politis</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Wiersum</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Richardson</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Renaudier</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Goto</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Grouzi</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The infectious risk of transfusion in the recipient: Istare data 2013-2016</article-title>. <source>Vox Sang.</source> <volume>114</volume>, <fpage>230</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/vox.12792</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogo</surname> <given-names>L. D.</given-names>
</name>
<name>
<surname>Mokhtari-Azad</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Kabir</surname> <given-names>M. H.</given-names>
</name>
<name>
<surname>Rezaei</surname> <given-names>F.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Human parvovirus B19: A review</article-title>. <source>Acta Virol.</source> <volume>58</volume>, <fpage>199</fpage>&#x2013;<lpage>213</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4149/av_2014_03_199</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahu</surname> <given-names>M. K.</given-names>
</name>
<name>
<surname>Siddharth</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Choudhury</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Vishnubhatla</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Menon</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Incidence, microbiological profile of nosocomial infections, and their antibiotic resistance patterns in a high volume cardiac surgical intensive care unit</article-title>. <source>Ann. Card. Anaesth.</source> <volume>19</volume>, <fpage>281</fpage>&#x2013;<lpage>287</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/0971-9784.179625</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenk</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Enders</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Pollak</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hahn</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Huzly</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy</article-title>. <source>J. Clin. Microbiol.</source> <volume>47</volume>, <fpage>106</fpage>&#x2013;<lpage>110</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/jcm.01672-08</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seng</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Watkins</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Morse</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Barrett</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Zambon</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Andrews</surname> <given-names>N.</given-names>
</name>
<etal/>
</person-group>. (<year>1994</year>). <article-title>Parvovirus B19 outbreak on an adult ward</article-title>. <source>Epidemiol. Infect.</source> <volume>113</volume>, <fpage>345</fpage>&#x2013;<lpage>353</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/s0950268800051773</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>S&#xf6;derlund-Venermo</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hokynar</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Nieminen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Rautakorpi</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Hedman</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Persistence of human parvovirus B19 in human tissues</article-title>. <source>Pathol. Biol. (Paris)</source> <volume>50</volume>, <fpage>307</fpage>&#x2013;<lpage>316</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0369-8114(02)00307-3</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szenborn</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>The use of immunoglobulins in the treatment of infectious diseases</article-title>. <source>Polski Merkur. Lek.</source> <volume>30</volume>, <fpage>441</fpage>&#x2013;<lpage>447</lpage>.</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrance</surname> <given-names>H. D. T.</given-names>
</name>
<name>
<surname>Longbottom</surname> <given-names>E. R.</given-names>
</name>
<name>
<surname>Vivian</surname> <given-names>M. E.</given-names>
</name>
<name>
<surname>Lalabekyan</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Abbott</surname> <given-names>T. E. F.</given-names>
</name>
<name>
<surname>Ackland</surname> <given-names>G. L.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Post-operative immune suppression is mediated <italic>via</italic> reversible, interleukin-10 dependent pathways in circulating monocytes following major abdominal surgery</article-title>. <source>PloS One</source> <volume>13</volume>, <elocation-id>e0203795</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0203795</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tournoux</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Karila-Cohen</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hvass</surname> <given-names>U.</given-names>
</name>
<name>
<surname>Peytavin</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Phelippeau</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Vahanian</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Neutropenia and fever after aorto-coronary bypasses</article-title>. <source>Ann. Chir.</source> <volume>129</volume>, <fpage>174</fpage>&#x2013;<lpage>176</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.anchir.2004.02.006</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volk</surname> <given-names>H. D.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Immunodepression in the surgical patient and increased susceptibility to infection</article-title>. <source>Crit. Care</source> <volume>6</volume>, <fpage>279</fpage>&#x2013;<lpage>281</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/cc1507</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname> <given-names>N. S.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>K. E.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Parvovirus B19</article-title>. <source>N. Engl. J. Med.</source> <volume>350</volume>, <fpage>586</fpage>&#x2013;<lpage>597</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMra030840</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>